Abstract
Adjuvant treatment with osimertinib significantly improves disease-free survival in patients with completely resected early-stage (IB-IIIA) EGFRm non-small cell lung cancer (NSCLC) compared with placebo, but the impact of osimertinib on societal economic costs is unknown. Here, we estimate the societal savings resulting from the use of adjuvant osimertinib vs. placebo in early-stage (IB-IIIA) EGFRm NSCLC in a United Kingdom (UK) setting.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
